Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX intraprostatic injection for lower urinary tract symptoms due to benign prostatic hyperplasia
2010-020172-30Phase 2Completed
- Sponsor
- Allergan
- Start
- Jun 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing BOTOX 200 U with Placebo (2 arms). Primary endpoint: Change in International Prostate Symptom Score. Started Jun 2010; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2010-020172-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020172-30.